200 related articles for article (PubMed ID: 11825543)
21. Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.
Ayres A; Bartholomeusz A; Lau G; Lam KC; Lee JY; Locarnini S
J Clin Virol; 2003 May; 27(1):111-6. PubMed ID: 12727536
[TBL] [Abstract][Full Text] [Related]
22. Chronic hepatitis B: interferon-monotherapy or combination with nucleoside analogues?
Tassopoulos NC
Liver; 1998 Apr; 18(2):71-2. PubMed ID: 9588765
[No Abstract] [Full Text] [Related]
23. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
Kanwal F; Gralnek IM; Martin P; Dulai GS; Farid M; Spiegel BM
Ann Intern Med; 2005 May; 142(10):821-31. PubMed ID: 15897532
[TBL] [Abstract][Full Text] [Related]
24. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
Perrillo R; Schiff E; Yoshida E; Statler A; Hirsch K; Wright T; Gutfreund K; Lamy P; Murray A
Hepatology; 2000 Jul; 32(1):129-34. PubMed ID: 10869300
[TBL] [Abstract][Full Text] [Related]
25. Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir.
Wolters LM; Hansen BE; Niesters HG; de Man RA
Eur J Gastroenterol Hepatol; 2002 Sep; 14(9):1007-11. PubMed ID: 12352221
[TBL] [Abstract][Full Text] [Related]
26. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study.
Serfaty L; Thabut D; Zoulim F; Andreani T; Chazouillères O; Carbonell N; Loria A; Poupon R
Hepatology; 2001 Sep; 34(3):573-7. PubMed ID: 11526544
[TBL] [Abstract][Full Text] [Related]
27. Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy?
Aloman C; Wands JR
Hepatology; 2003 Dec; 38(6):1584-7. PubMed ID: 14655682
[No Abstract] [Full Text] [Related]
28. Clinical potential of emerging new agents in hepatitis B.
Farrell GC
Drugs; 2000 Oct; 60(4):701-10. PubMed ID: 11085196
[TBL] [Abstract][Full Text] [Related]
29. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
30. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
Marcellin P; Lau GK; Bonino F; Farci P; Hadziyannis S; Jin R; Lu ZM; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Button P; Pluck N;
N Engl J Med; 2004 Sep; 351(12):1206-17. PubMed ID: 15371578
[TBL] [Abstract][Full Text] [Related]
31. Management of viral hepatitis B.
Pramoolsinsup C
J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S125-45. PubMed ID: 12000599
[TBL] [Abstract][Full Text] [Related]
32. [Famciclovir treatment of patients with chronic hepatitis B virus infection].
Li L; Shao Q; Zhang J; Ji D
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Dec; 16(4):390-1. PubMed ID: 12665916
[TBL] [Abstract][Full Text] [Related]
33. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.
Chang UI; Lee YC; Wie SH; Jang JW; Bae SH; Choi JY; Yang JM; Yoon SK; Sun HS
J Med Virol; 2007 Jul; 79(7):902-10. PubMed ID: 17516533
[TBL] [Abstract][Full Text] [Related]
34. Interferon-α combined with lamivudine versus lamivudine monotherapy for the emergence of YMDD mutations in chronic hepatitis B infection: a meta-analysis of randomized controlled trials.
Zhang YL; Zhang J; Cui LY
Hepatogastroenterology; 2015; 62(137):133-9. PubMed ID: 25911883
[TBL] [Abstract][Full Text] [Related]
35. Treatment with interferons (including pegylated interferons) in patients with hepatitis B.
Cooksley WG
Semin Liver Dis; 2004; 24 Suppl 1():45-53. PubMed ID: 15192801
[TBL] [Abstract][Full Text] [Related]
36. Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine.
Meisel H; Preikschat P; Reinke P; Hocher B; Budde K; Bechstein WO; Neuhaus P; Krüger DH; Neumayer HH
Transpl Int; 1999; 12(4):283-7. PubMed ID: 10460876
[TBL] [Abstract][Full Text] [Related]
37. Nucleoside analogues in the treatment of chronic hepatitis B.
Leung N
J Gastroenterol Hepatol; 2000 May; 15 Suppl():E53-60. PubMed ID: 10921383
[TBL] [Abstract][Full Text] [Related]
38. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.
de Man RA; Bartholomeusz AI; Niesters HG; Zondervan PE; Locarnini SA
J Hepatol; 1998 Oct; 29(4):669-75. PubMed ID: 9824278
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients.
Guptan RC; Thakur V; Kazim SN; Sarin SK
J Gastroenterol Hepatol; 2002 Jul; 17(7):765-71. PubMed ID: 12121506
[TBL] [Abstract][Full Text] [Related]
40. [Current treatment of hepatitis B].
Suárez García E; Romero Gómez M; Grande Santamaría L
Gastroenterol Hepatol; 2001 Feb; 24 Suppl 1():35-50. PubMed ID: 11279893
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]